Lytle T, Coles S, Waite M A
Medical Department, Abbott Laboratories, Maidenhead, UK.
J Hum Hypertens. 1991 Feb;5(1):35-8.
The safety, efficacy and the effect on the plasma total cholesterol of once-daily terazosin hydrochloride administered as monotherapy was evaluated in 69 patients with mild-moderate untreated essential hypertension in this open, hospital, multi-centre, 3 month study. Patients initially received 1 mg of terazosin followed by dose titration, if necessary, to a maximum of 10 mg over the first six weeks depending upon blood pressure control. Patients then continued treatment for a further six weeks on their optimum dosage. At the end of 12 weeks' treatment, there were highly significant mean reductions in systolic and diastolic blood pressures of 14.5 and 12.9 mmHg (P less than 0.001), respectively, as well as a significant reduction in the mean total cholesterol of -0.56 mmol/l (-9.5%, P less than 0.01). No serious toxicity or safety problems were observed. Once daily administration of terazosin proved to be safe and effective in reducing the blood pressure of patients with mild-moderate essential hypertension and favourably reduced the total plasma cholesterol level.
在这项开放、医院内、多中心、为期3个月的研究中，对69例未经治疗的轻度至中度原发性高血压患者评估了每日一次单药使用盐酸特拉唑嗪的安全性、有效性及其对血浆总胆固醇的影响。患者最初接受1毫克特拉唑嗪治疗，如有必要，在头六周内根据血压控制情况将剂量滴定至最大10毫克。然后患者继续以最佳剂量治疗六周。在12周治疗结束时，收缩压和舒张压平均显著降低，分别为14.5和12.9毫米汞柱（P小于0.001），平均总胆固醇也显著降低-0.56毫摩尔/升（-9.5%，P小于0.01）。未观察到严重毒性或安全问题。每日一次服用特拉唑嗪被证明在降低轻度至中度原发性高血压患者血压方面是安全有效的，并能有效降低血浆总胆固醇水平。
